Robotics and the Medical Device Supply Chain

Like the disposables revolution of the 1960s and the rise of minimally invasive surgery in the 1980s, robotic surgery is proving to be one of the great advancements in medical technology. The global surgical robotics market—valued at roughly $14 billion in 2025—is projected to grow nearly 15% annually through 2030. Behind the statistics, though, is a fundamental restructuring of how surgery is performed—and, by extension, how the devices that enable these procedures are designed, sourced, and manufactured. Suppliers of components, sub-assemblies, and materials will find this shift is neither purely good news nor bad. It does, however, compel companies to strategize for effectively riding the robot wave.

A Threat to Traditional MIS Suppliers

The rising use of medical robots will cut demand for traditional multiport laparoscopy, particularly across high-volume general and gynecological procedures. The most immediate impacts are and will be on high-volume devices for general, gynecology, and urology procedures. Significantly affected are cholecystectomy, hernia repair, colorectal procedures, prostatectomy, and hysterectomy. In orthopedics, more than half of knee replacements are performed with robotic assistance. These are not niche procedures—they represent tens of millions of cases annually. They also tie to the high-volume production runs that many contract manufacturers have structured their factories and supply chains in which to serve. 

The shift is structural. More than 85% of prostatectomies performed in the United States are now conducted with robotic assistance—a significant procedural change from the predominantly manually performed procedure only 25 years ago. This shift to robotic support in prostate surgery is also occurring in other soft-tissue and orthopedic operations as well as cardiac, ophthalmological, oncological, and dental procedures. 

A Larger Opportunity 

The surgical robotics market has not displaced traditional MIS; rather, it is creating a larger, more complex, and more demanding device category that requires a different supply base. Consider the bill of materials for an Intuitive da Vinci or Stryker Mako system versus a standard laparoscopic instrument set. Surgical robots require precision robotic arms, motion controls, sensors, and advanced imaging components. The precision requirements, materials specifications, and quality standards that govern robotic components are often more demanding than those for conventional instruments—and, not surprisingly, the per-unit value of components is higher.

There is also a recurring revenue benefit for the supply chain. Many robotic instruments have replacement cycles of 10 to 15 uses, meaning that every robotic procedure drives consumable demand in a way that reusable traditional instruments do not. For suppliers of precision-machined components, specialty coatings, or sub-assemblies, this creates a durable, volume-driven demand stream rather than a one-time capital purchase.

Is there an opportunity for contract manufacturers without robotic programs? With more than 100 robotic startups ranging from general surgery competitors to market leaders like Intuitive to highly specialized single-procedure-only specialist offerings, the growth in the market means there are large opportunities to come. Choosing the specific startups that will scale will be difficult, but the large OEMs have increasingly been purchasing startups as a way of launching or enhancing their robotic offerings.

What Robotic OEMs Need From Suppliers

Understanding what robotic surgery OEMs need is the critical factor for success. The requirements, however, differ from traditional MIS in several ways.

Tighter tolerances. The movements required for robotic-assisted surgery depend on the exact meshing of precision gears, actuators, cables, and controls. The ability to work at sub-micron tolerances on components with complex geometries is essential in this space. While traditional devices require extraordinary precision, the complex array of components making up most robotic systems calls for exceptional engineering and execution.

Broader process capability. Contract manufacturers in robotic surgery must support a range of capabilities, including motion control assemblies, sensor-integrated tools, sterile housings, control systems, cleanroom environments for sterile and high-precision builds, and advanced surfaces. Suppliers who offer only a single process are less attractive than those who can serve as a more complete manufacturing partner.

Early design-for-manufacturability engagement. Robotic surgery OEMs—especially emerging challengers who are racing toward a 510(k) clearance (or other global equivalents) on compressed timelines need suppliers who can help them avoid mistakes in the design process. A contract manufacturer that can work closely with the medical device company in a collaborative environment to innovate and refine products through design for manufacturing (DFM) is desirable. While DFM is valuable to constructing most devices, it is likely essential in the Wild West atmosphere of today’s medical robotics. 

Scalability and supply chain resilience. Robotic surgery platforms have complex, multi-tier supply chains with long qualification timelines. OEMs cannot afford sole-source dependencies that might fail at volume. Proven ability to manage a global supply chain, including outsourced service vendors (design, materials, coatings, etc.), as well as demonstrating a strong plan to scale production, is crucial.

Quality systems beyond the basics. ISO 13485 certification is the floor, not the ceiling. OEMs sourcing components for robotic systems require documented process control, low PPM scores, and suppliers with robust corrective action and remediation processes. Robotic systems are intricate, and the successful delivery of a production order requires a perfectly conducted orchestra of competencies throughout the process.

Five Essential Steps to Winning Robotic-Related Contracts

1. Audit capabilities against robotic requirements. Suppliers must start with a gap analysis. Where does the precision machining capability stand relative to the tolerances robotic OEMs require? Supply firms should consider cleanroom capacity and whether they can perform or source the surface treatments that biocompatibility and durability standards demand. Companies also must determine whether they have sufficient knowledge of electronic components and integration. Knowing the gaps is necessary to closing them.

2. Look at emerging challengers. Intuitive Surgical Inc. has a well-curated, entrenched supply chain. The better opportunity for most contract manufacturers lies with newer entrants now scaling—Medtronic’s Hugo system, Johnson & Johnson MedTech’s OTTAVA, CMR Surgical’s Versius, and a growing roster of startups. Recent major developments include Johnson & Johnson MedTech submitting a De Novo application to the U.S. Food and Drug Administration (FDA) for the OTTAVA robotic system and Medtronic’s Stealth AXiS spinal navigation system obtaining FDA clearance in early 2026, signaling active procurement cycles for new component suppliers.

3. Invest in the recurring consumables business. The instruments and accessories segment represents the largest share of the surgical robotics market, driven by the recurring purchase of instruments and accessories rather than robotic systems themselves. Suppliers that can qualify and scale production of robotic end effectors, wristed instrument components, and disposable accessories will benefit from procedure volume growth.

4. Develop DFM capability as a sales tool. Many robotic surgery OEMs—particularly venture-backed startups and mid-size challengers—lack the engineering bench they need to take a product to market by themselves. A contract manufacturer that can demonstrate its value at the design table becomes a partner rather than a vendor. The partnership path, though, requires investments in application engineering talent and a willingness to work on a development timeline before production revenues materialize. It also necessitates leading the marketing and sales effort by identifying the company’s specific expertise areas. General “we are good at DFM” statements won’t work. Lead with demonstrable strengths.

5. Don’t abandon traditional MIS entirely; evolve with it. The traditional laparoscopic device market is not disappearing. The U.S. laparoscopic device sector will expand moderately through 2033, driven by growing demand for devices designed for robotic procedures—such as robotic trocars and hand instruments—and the higher prices associated with these advanced devices. The traditional MIS device market is hybridizing with robotics, and suppliers who understand both worlds will have the advantage.

The Window Is Open

The medical robotics supply chain is still being built. New OEMs are qualifying suppliers, establishing long-term partnerships, and looking for the vendor relationships that will define their cost structure. No one has missed the boat— yet. The key is to tailor offerings to the unique needs of robotic medical programs rather than what has worked in the past for traditional devices.

The companies that wait and watch risk flat to declining volume in traditional MIS orders and exclusion from the robotic ecosystem. For contract manufacturers, the operating room of the future is being designed and built today.

MORE FROM THIS AUTHOR: The ‘Drag’ on U.S. Medtech From Healthcare Funding Cuts

Tony Freeman is the president of A.S. Freeman Advisors LLC. Based in New York City, the company specializes in advising specialty materials and precision manufacturing firms on corporate strategy and in mergers and acquisitions. He is currently recording an acoustic guitar treatment of the Ramones’ greatest hits.